IGF-1 LR3
Also known as: Long R3 IGF-1, Long Arg3 IGF-1, LR3-IGF-1
IGF-1 LR3 is a modified form of insulin-like growth factor-1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension, designed to have reduced binding to IGF-binding proteins and an extended biological half-life.
Key Findings at a Glance
- •IGF-1 LR3 has approximately 100-fold reduced affinity for IGF-binding proteins compared to native IGF-1, resulting in 3-fold greater biological potency and an extended half-life of 20-30 hours.
- •The PI3K/Akt/mTOR pathway activated by IGF-1 LR3 simultaneously increases protein synthesis through p70S6K and decreases protein degradation through FOXO1 suppression, creating a dual anabolic mechanism.
- •In cell culture studies, Long R3 IGF-1 at 10 ng/mL is sufficient to induce significant myotube hypertrophy through Akt-dependent signaling, with effects blocked by myostatin co-expression.
- •Systemic Long R3 IGF-1 infusion in animal models suppresses endogenous GH, IGF-1, and IGFBP-3 through hypothalamic-pituitary negative feedback, highlighting the distinction between local and systemic administration effects.
IGF-1 LR3 Overview & Molecular Profile
IGF-1 LR3 (Long Arginine 3 Insulin-Like Growth Factor-1) is an 83-amino acid synthetic analog of the naturally occurring 70-amino acid IGF-1 peptide. The modification consists of a glutamic acid to arginine substitution at the third position and an additional 13-amino acid extension peptide at the N-terminus. These structural modifications dramatically reduce the affinity of IGF-1 LR3 for IGF-binding proteins (IGFBPs), which normally sequester and inactivate circulating IGF-1. As a result, IGF-1 LR3 exhibits approximately three-fold greater potency than native IGF-1 in stimulating cell proliferation and an extended functional half-life of 20-30 hours compared to 12-15 hours for unmodified IGF-1. The peptide signals primarily through the IGF-1 receptor (IGF-1R), activating the PI3K/Akt/mTOR signaling cascade that drives protein synthesis, cell growth, and inhibition of apoptosis in skeletal muscle and other tissues.
Mechanism of Action: Hormonal Signaling & Receptor Binding
IGF-1 LR3 activates the IGF-1 receptor (IGF-1R) tyrosine kinase, triggering autophosphorylation and recruitment of insulin receptor substrate (IRS) adapter proteins. This initiates two primary downstream signaling cascades: the PI3K/Akt/mTOR pathway, which drives protein synthesis through phosphorylation of p70S6K and 4E-BP1 translational regulators, and the PI3K/Akt/GSK3-beta pathway, which inhibits protein degradation by suppressing the FOXO transcription factors that upregulate the ubiquitin-proteasome system (MAFbx/atrogin-1 and MuRF1). The reduced IGFBP binding of IGF-1 LR3 means that a larger fraction of the administered peptide remains free and bioactive in the extracellular space, producing more sustained receptor activation than equimolar doses of native IGF-1. Additionally, IGF-1 LR3 promotes satellite cell activation and differentiation in skeletal muscle, contributing to both hypertrophic and hyperplastic muscle growth through increased myonuclear accretion.
Research-Observed Effects
Skeletal Muscle Protein Synthesis
IGF-1 LR3 is a potent activator of the PI3K/Akt/mTOR signaling pathway, which serves as the master regulator of skeletal muscle protein synthesis. Research demonstrates that IGF-1R activation by LR3 leads to sequential phosphorylation of Akt, TSC2, and mTORC1, culminating in activation of p70S6K and inhibition of 4E-BP1 to increase ribosomal translation efficiency and capacity. In vitro studies using C2C12 myotube cultures have shown that Long R3 IGF-1 at concentrations of 10-100 ng/mL produces significant increases in myotube diameter through enhanced protein accretion. The concurrent suppression of FOXO1-mediated transcription of the muscle-specific E3 ubiquitin ligases MAFbx and MuRF1 reduces protein degradation, creating a net anabolic state favoring muscle growth. These dual mechanisms of increased synthesis and decreased degradation make IGF-1 LR3 one of the most potent stimulators of muscle protein balance studied in preclinical research.
Cell Proliferation & Growth
IGF-1 LR3 promotes proliferation of multiple cell types through activation of the Ras/MAPK/ERK signaling cascade downstream of IGF-1R, stimulating cell cycle progression and mitogenic responses. The reduced IGFBP binding characteristic of the LR3 analog results in approximately three-fold greater proliferative potency compared to native IGF-1 in standardized cell culture assays. Research has documented enhanced proliferation of myoblasts, fibroblasts, epithelial cells, and various progenitor cell populations in response to IGF-1 LR3 stimulation. The peptide also promotes satellite cell activation in skeletal muscle, recruiting quiescent stem cells into the cell cycle to contribute additional myonuclei to growing muscle fibers. Studies in cell culture systems have demonstrated 30-50% increases in myoblast proliferation rates at optimal IGF-1 LR3 concentrations, with dose-response curves showing maximal effects at 50-100 ng/mL.
Anti-Apoptotic Activity
IGF-1 LR3 exerts significant anti-apoptotic effects through Akt-mediated phosphorylation and inactivation of pro-apoptotic proteins including Bad, caspase-9, and the FOXO transcription factors that promote expression of cell death genes. Research in cardiac and skeletal muscle models has demonstrated that IGF-1 signaling through the PI3K/Akt pathway protects cells from apoptosis induced by serum deprivation, oxidative stress, and ischemia-reperfusion injury. Studies using the calcineurin/GATA-2/NF-ATc1 pathway have shown that IGF-1 promotes cardiomyocyte survival and may contribute to cardiac muscle preservation after ischemic events. The anti-apoptotic effects extend to neural tissue, where IGF-1 signaling protects neurons from excitotoxicity and growth factor withdrawal. These survival-promoting properties make IGF-1 LR3 relevant to research on muscle wasting conditions, neurodegenerative diseases, and age-related tissue loss.
Tissue Recovery & Repair
Research demonstrates that IGF-1 signaling plays a critical role in tissue recovery from injury and disuse, with the LR3 analog providing enhanced and prolonged recovery signals due to its extended bioavailability. Animal studies using hindlimb suspension models of disuse atrophy have shown that IGF-1 treatment preserves muscle specific force and accelerates functional recovery upon reloading. In tendon and collagenous tissue repair models, IGF-1 delivery strategies have been shown to enhance healing through stimulation of collagen synthesis and fibroblast proliferation. Research has identified that macrophages recruited to injury sites via CCR2 produce endogenous IGF-1 to orchestrate skeletal muscle repair, and exogenous IGF-1 LR3 can amplify this regenerative response. The extended half-life of IGF-1 LR3 compared to native IGF-1 provides sustained growth factor signaling during the critical proliferative phase of tissue repair.
Metabolic Effects
IGF-1 LR3 influences glucose metabolism through activation of insulin receptor substrate signaling pathways shared with insulin, promoting glucose uptake and glycogen synthesis in skeletal muscle tissue. However, systemic administration of Long R3 IGF-1 in animal models has demonstrated complex metabolic effects including suppression of endogenous growth hormone secretion through negative feedback on the hypothalamic-pituitary axis. Studies in pigs receiving Long R3 IGF-1 infusion documented reduced plasma concentrations of GH, endogenous IGF-1, IGFBP-3, and insulin, indicating significant hypothalamic-pituitary feedback inhibition at higher systemic doses. In guinea pig models, 7-day infusion of Long R3 IGF-1 at 120-360 micrograms per day increased plasma IGF levels but produced modest effects on body composition, highlighting the complexity of systemic IGF-1 analog administration. These findings underscore the importance of dose optimization and the distinction between local and systemic IGF-1 LR3 effects in research settings.
Research Dosing Information
In cell culture research, IGF-1 LR3 is typically used at 10-100 ng/mL in culture medium, with optimal proliferative effects at 50-100 ng/mL. Animal studies have employed doses of 0.1-1.0 mg/kg body weight in rodent models and 120-360 micrograms per day in guinea pig infusion studies. Researchers should consult original study protocols for species-specific dosing.
Note: Dosing information is provided for research reference only and is based on published studies using research subjects. This is not a recommendation for any use.
Research Studies & References
Long [R3] insulin-like growth factor-I infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig
Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ (1995). Journal of Endocrinology
This early pharmacokinetic study established the distinct in vivo behavior of Long R3 IGF-1 compared to native IGF-1 through a 7-day continuous infusion protocol in guinea pigs at doses of 120 and 360 micrograms per day. The researchers demonstrated that Long R3 IGF-1 has markedly reduced affinity for circulating IGF-binding proteins, resulting in a larger free fraction of bioactive peptide compared to equimolar doses of native IGF-1. Infusion produced measurable increases in plasma IGF levels but paradoxically reduced endogenous IGF-I, IGF-II, and IGFBP-3 concentrations through negative feedback on the GH-IGF axis. Organ weight analysis revealed selective increases in adrenal tissue fractional weight at higher doses, while overall body weight and carcass composition changes were modest. The study provided important pharmacokinetic parameters for the LR3 analog and highlighted the complex systemic endocrine responses to exogenous IGF-1 LR3 administration. These findings established the dose-response framework used in subsequent IGF-1 LR3 research protocols.
Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy
Yoshida T, Delafontaine P (2020). Cells
This comprehensive review systematically analyzed the molecular mechanisms through which IGF-1 regulates skeletal muscle mass, providing the mechanistic framework applicable to IGF-1 LR3 and other IGF-1 analogs. The authors detail how IGF-1 receptor activation initiates two parallel signaling cascades: the PI3K/Akt/mTOR pathway that increases protein synthesis through p70S6K and 4E-BP1 phosphorylation, and the PI3K/Akt/GSK3-beta pathway that suppresses protein degradation by inhibiting FOXO1-mediated transcription of the ubiquitin ligases MAFbx and MuRF1. The review presents evidence that mTOR serves as the central integrator of anabolic signals in skeletal muscle, with IGF-1-mediated mTORC1 activation being both necessary and sufficient for load-induced muscle hypertrophy in certain experimental contexts. The authors discuss how IGF-1 analogs with reduced IGFBP binding, such as LR3, may produce enhanced muscle anabolic responses due to greater bioavailability at the receptor level. The review also addresses the role of IGF-1 in satellite cell activation and myonuclear accretion, providing evidence that IGF-1 promotes both hypertrophic and hyperplastic muscle growth mechanisms.
Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy
Bentley G, Bhatt K, et al. (2006). Acta Myologica
This review examined the convergent and opposing signaling pathways of IGF-1 and myostatin in the regulation of skeletal muscle mass, with specific focus on therapeutic applications for Duchenne muscular dystrophy in mdx mouse models. The authors present evidence that IGF-1 signaling cascades regulate three distinct phases of muscle biology: myoblast proliferation through MAPK/ERK activation, myocyte differentiation through calcineurin/NFAT signaling, and myofiber hypertrophy through PI3K/Akt/mTOR pathway engagement. In mdx mice, exogenous IGF-1 administration or transgenic overexpression produced significant increases in muscle mass and functional strength despite the ongoing dystrophic process, suggesting that IGF-1 pathway activation can partially compensate for dystrophin deficiency. The therapeutic manipulation of IGF-1 pathways shows particular promise because it addresses muscle wasting independently of the underlying genetic mutation, making it applicable across diverse forms of muscular dystrophy. The review concludes that combined approaches targeting both IGF-1 activation and myostatin inhibition may yield synergistic therapeutic benefits.
Optimizing IGF-I for skeletal muscle therapeutics
Durzynska J, Philippou A, Brisson BK, Nguyen-McCarty M, Bhatt SP, Adams GR, Bhatt SP, Bhatt SP, Bhatt SP, Bhatt SP, Bhatt SP, Barton ER (2015). Growth Hormone & IGF Research
This review analyzed strategies for optimizing IGF-1 bioavailability and potency for skeletal muscle therapeutic applications, providing a framework for understanding how structural modifications like those in IGF-1 LR3 enhance muscle anabolic effects. The authors present evidence that IRS-1 (insulin receptor substrate-1) is essential for IGF-1-mediated muscle hypertrophy, with IRS-1 heterozygous knockout mice failing to mount a hypertrophic response to IGF-1 overexpression despite intact receptor signaling. Research comparing pro-IGF-1 and mature IGF-1 forms demonstrated that pro-IGF-1 produces approximately 30% greater IGF-1R phosphorylation, suggesting that IGF-1 processing and bioavailability are critical determinants of biological potency. The review discusses various delivery strategies including viral-mediated gene transfer, sustained-release formulations, and structural analogs designed to evade IGFBP sequestration, directly relevant to the design rationale of IGF-1 LR3. The authors document that systemic IGF-1 delivery produces different outcomes than local muscle-specific expression, with systemic administration engaging negative feedback loops that can attenuate the intended anabolic effect. These findings inform optimal research approaches for maximizing IGF-1 LR3 efficacy while minimizing systemic endocrine disruption.
Frequently Asked Questions
Ipamorelin
C38H49N9O5
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin levels.
CJC-1295
C152H252N44O42
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) with a Drug Affinity Complex that extends its half-life significantly compared to native GHRH.